A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs CFZ 533 (Primary) ; Ianalumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 04 Feb 2019 Planned End Date changed from 25 Jan 2024 to 18 Apr 2024.
- 04 Feb 2019 Planned primary completion date changed from 6 Jan 2021 to 31 Mar 2021.
- 04 Feb 2019 Status changed from not yet recruiting to recruiting.